OPEN END TURBO OHNE STOP-LOSS - VIVORYON THERAPEUTICS | Market Closed - Bid/Ask 02:11:36 2024-05-23 EDT | After market 15:17:11 | |||
| 0.48 EUR | +37.14% |
|
0.95 | +97.92% |
| Current month | +12.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VIVORYON THERAPEUTICS N.V.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 0.48 | +37.14% |
| 24-05-22 | 0.35 | -5.41% |
| 24-05-21 | 0.37 | +2.78% |
| 24-05-20 | 0.36 | +20.00% |
| 24-05-17 | 0.3 | -3.23% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 02:11 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VIVORYON THERAPEUTICS N.V. |
| Issuer | Lang & Schwarz |
| WKN | LX34NS |
| ISIN | DE000LX34NS8 |
| Date issued | 2024-04-24 |
| Strike | 0.4529 € |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 0.55 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.6 € |
|---|---|
| Lowest since issue | 0.22 € |
| Spread | 0.3 € |
| Spread % | 26.79% |
Company Profile
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Sector
-
Consensus: Vivoryon Therapeutics N.V.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.821
EUR
Average target price
41.57
EUR
Spread / Average Target
+4,962.93%
- Stock Market
- Certificates
- Certificat
